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Background: Primary cilia are microtubule-based organelles that protrude from the cell surface. Primary cilia play a
critical role in development and disease through regulation of signaling pathways including the Hedgehog pathway.
Recent mouse models have also linked ciliary dysfunction to cancer. However, little is known about the role of primary
cilia in breast cancer development. Primary cilia expression was characterized in cancer cells as well as their surrounding
stromal cells from 86 breast cancer patients by counting cilia and measuring cilia length. In addition, we examined
cilia expression in normal epithelial and stromal cells from reduction mammoplasties as well as histologically
normal adjacent tissue for comparison.
Results: We observed a statistically significant decrease in the percentage of ciliated cells on both premalignant
lesions as well as in invasive cancers. This loss of cilia does not correlate with increased proliferative index (Ki67-positive
cells). However, we did detect rare ciliated cancer cells present in patients with invasive breast cancer and found that
these express a marker of basaloid cancers that is associated with poor prognosis (Cytokeratin 5). Interestingly, the
percentage of ciliated stromal cells associated with both premalignant and invasive cancers decreased when
compared to stromal cells associated with normal tissue. To understand how cilia may be lost during cancer
development we analyzed the expression of genes required for ciliogenesis and/or ciliary function and compared
their expression in normal versus breast cancer samples. We found that expression of ciliary genes were frequently
downregulated in human breast cancers.
Conclusions: These data suggest that primary cilia are lost early in breast cancer development on both the cancer
cells and their surrounding stromal cells.
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Primary cilia are hair-like projections that extend from
the plasma membrane and are found on many types of
normal eukaryotic cells. Cells with primary cilia have a
single cilium that is non-motile. Ciliary structure includes
the basal body (also known as the mother centriole),
which is anchored into the plasma membrane to nucleate
microtubules of the ciliary axoneme. Ciliary assembly (or
ciliogenesis) is regulated by a process known as intraflagel-
lar transport (IFT), by which proteins are trafficked to the* Correspondence: kmcdermott@azcc.arizona.edu
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2014cilium and move along the ciliary microtubules via kinesin
and dynein. IFT also regulates ciliary sensory functions,
allowing the organelle to respond to physical and chemical
signals to regulate critical signaling transduction pathways;
for example, cilia are both negative and positive regulators
of the Hedgehog pathway [1]. Cilia are known to play crit-
ical roles in developmental biology and mutations in genes
required for ciliogenesis or ciliary function are associated
with human genetic disorders collectively known as ciliopa-
thies (for example, Joubert syndrome, polycystic kidney
disease, Bardet-Biedl syndrome, and nephronophthisis) [2].
The role primary cilia play in cancer is not well under-
stood [3,4]. Mouse models demonstrate that loss of cilia
can increase tumor incidence in basal cell carcinoma and
medulloblastoma [5-7]. Cilia expression has been analyzed
in some human cancers, demonstrating that pancreatictd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Menzl et al. Cilia Page 2 of 162014, 3:7
http://www.ciliajournal.com/content/3/1/7cancer, renal cell carcinoma, cholangiocarcinoma, melan-
oma, ovarian cancer, and prostate cancer all have a general
loss of cilia [8-14]. These studies suggest that loss of cilia
may promote cancer development in some tissues. We
have also put forth the hypothesis that presence or ab-
sence of cilia may regulate targeted drug efficacy (that
is, Hedgehog targeted drugs) [3]. In order to better under-
stand the role of cilia in cancer and targeted drug efficacy,
it is critical to have a comprehensive analysis of cilia
expression in all human cancers.
Very little is known about the role of cilia in breast
cancer development. Studies have demonstrated that
human breast cancer cell lines have a low frequency of
primary cilia [15]. A small number of human breast
cancer tissue samples have also been analyzed for cilia
demonstrating that cilia are lost in 8/9 patient samples
in the first study and 11/11 patient samples in a second
study [15,16]. Our current study is aimed at characterizing
primary cilia frequency in a larger, more comprehensive
breast cancer cohort and to expand our knowledge to
analyze cilia in premalignant breast cancer lesions. We an-
alyzed pre-invasive and invasive breast cancers of low and
high-grade tumors that include all four major subtypes
(Luminal A, Luminal B, Her2+, and Triple Negative). We
demonstrate that primary cilia frequency is decreased in
all stages and subtypes of breast cancer. Interestingly, we
find that cilia are lost on pre-invasive breast cancer lesions
suggesting that this is an early event in cancer develop-
ment. We further demonstrate that expression of genes
required for ciliogenesis and ciliary function are frequently
downregulated in human breast cancers.
Methods
Tissue cohort
Paraffin-embedded serial sections from 86 breast cancer
patients were acquired from the Tissue Acquisition and
Cellular/Molecular Analysis Shared Service (TACMASS)
core facility of the University of Arizona Cancer Center
under an IRB-approved protocol (protocol #: 05-0337-01).
Normal and pathological features were characterized
and carcinoma in situ and invasive cancers were graded
using the Nottingham grading system, which is based
on scoring nuclear grade, tubule formation, and mi-
totic rate of cancer cells. The combined scores result
in the grade of the cancer (1, 2, or 3) with 1 being the
lowest and 3 being the highest (least favorable). Four
breast cancer subtypes were categorized for the inva-
sive cancers based on the expression of standard breast
cancer molecular markers: luminal A (ER+ and/or PR+,
Her2-), luminal B (ER+ and/or PR+, Her2+), Her2+
(Her2+, ER-, PR-), and triple-negative (Her2-, ER-, PR-).
Paraffin-embedded breast tissue sections from 12 cancer-
free patients who underwent reduction mammoplasty
(RM) were also assessed.The first cut serial section of each patient sample was
stained for Hematoxylin and Eosin (H&E) and digitally
scanned using a DMetrix microscope slide scanner (EX-40
wide scanner, DMetrix, Inc.) with 20× optical resolution.
The H&E slides were histologically examined by a certified
pathologist (Lauren G. LeBeau, MD or Ray Nagle, MD) to
annotate areas that correspond to normal, carcinoma in
situ, and invasive cancer. These annotated locations were
then identified on the next serial sections and analyzed for
expression of cilia.
Immunofluorescence
Tissue sections adjacent to those that had been stained
for H&E were deparaffinized with xylene (2 × 10 min at
room temperature) and rehydrated with decreasing iso-
propanol concentrations (2 × 100%, 1 × 70%, 1 × 50%, each
for 10 min at room temperature) and water (2 × 10 min at
room temperature). Antigen retrieval was performed in a
1 mM EDTA solution using a 2100 Retriever (Electron
Microscopy Sciences). After washing with PBS (5 min),
slides were placed into a Shandon Sequenza (Thermo
Scientific) using immunostaining chambers (Shandon
Coverplate, Thermo Scientific) and blocked for 45 min
at room temperature with Antibody Dilution Buffer
(Ventana Medical Systems, Inc.) containing 5% goat serum
(Invitrogen Corporation). This buffer was also used as the
diluent for all antibodies. Tissue was incubated with pri-
mary antibodies against Cytokeratin 5 (CK5) (1:300, rabbit
polyclonal IgG, abcam, Cat # ab53121), acetylated tubulin
(1:1,000, mouse monoclonal IgG2B, Sigma, Cat # T7451)
Arl13b (1:300, mouse monoclonal IgG2a, UC, Davis/NIH
NeuroMab Facility, clone N295B/66), γ-tubulin (1:1,000,
mouse monoclonal IgG1, Sigma, Cat # T5326), and
DYNC2H1 (1:100, rabbit polyclonal, gift from Dr. Richard
Vallee) overnight at 4°C. After incubation slides were
washed with PBS (3 × 10 min) and the following secondary
antibodies were applied for 45 min at room temperature:
fluorescein isothiocyanate (FITC)-labeled goat anti-rabbit
(1:1,000, IgG, Southern Biotech, Cat # 4052-02), tetra-
methylrhodamine isothiocyanate (TRITC)-labeled goat
anti-mouse (1:1,000, IgG2B, Southern Biotech, Cat #
1090-03) Alexa 546-labeled goat anti-mouse-IgG2a
(Invitrogen, Cat#A21133) and goat anti-mouse fluores-
cently labeled with Alexa 633 (1:1,000, IgG1, Invitrogen,
Cat # A21126). Following washing with PBS (3 × 10 min),
DNA was counterstained with Hoechst 33342 (Invitrogen)
for 10 min. After washing with PBS (2 × 5 min), sam-
ples were mounted with Prolong Gold Antifade Reagent
(Invitrogen).
Confocal microscopy
Immunofluorescence of the annotated locations was an-
alyzed using a Leica TCS SP5 II laser scanning confocal
microscope (Leica Microsystems). The 10× dry objective
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find the necessary locations as defined as a region of
interest on the serial adjacent H&E slide. The image was
acquired with the violet-laser diode at 405 nm detecting
the nuclear staining (Hoechst 33342). After switching to
the 63× oil objective (63×/1.4 NA PL Apo), three to five
images per location were selected and a series of optical
sections (z-stack) with a total thickness of 6 ± 0.5 μm
was captured. The z-step size was 0.34 μm and the image
resolution acquired was 2048 × 2048 pixels. In addition to
the violet-laser diode, additional fluorescence signals were
detected with the argon laser (excitation 488 nm) and the
helium neon lasers (excitation 543 nm and excitation
633 nm). Projections of the entire z-stack were computed
post-acquisition with the Leica Software using the max-
imum projection tool creating a 2D projection.
Analysis of confocal images
Cilia frequency and length were determined by counting
cilia per cell type and measuring length using the Leica
Software counter tool and scale bar tool, respectively. A
minimum of 3,800 nuclei were counted per tissue type
(Additional file 1: Tables). A primary cilium was con-
sidered as such if a ciliary acetylated tubulin structure,
marker for the axoneme, was attached to a γ-tubulin
spot, marker for centrosomes, and if the minimum
length of the axoneme was 0.1 μm. The counting of
cilia was done manually and a cilium was counted if
the acetylated-tubulin axoneme was immediately adja-
cent to the γ-tubulin basal body (see Figure 1A inset).
Cells on the edge of an image were excluded. Our con-
focal acquisition settings were optimized using a set of
normal and cancer mammary tissue and no thresholds
were applied during the analysis to maintain consistency
of scoring across samples. Measuring the length of the
cilium included measuring the acetylated tubulin (axo-
neme) staining and did not include the γ-tubulin staining
(centrosome). Frequency of cilia was determined by divid-
ing the number of ciliated cells by the total number of
nuclei. Cilia frequency was determined for epithelial cells,
both basal and luminal, as well as stromal cells. The two
different cell types, basal and luminal, that form a normal
duct, were identified based on their shape and positioning
in the duct: the shape of a basal cell is more elongated as
opposed to the shape of a luminal cell. In addition, basal
cells touch the stroma, whereas a luminal cell was
identified as luminal if it touched the lumen of the duct.
Stromal cells include all non-epithelial cell types, which
were not further characterized.
Immunohistochemistry
Tissue sections adjacent to those that had been stained
for cilia were deparaffinized and rehydrated as described
above. Antigen retrieval was performed using 1 mM EDTAsolution in the 2100 Retriever followed by quenching of en-
dogenous peroxidase activity in a 0.3% H2O2/methanol so-
lution for 20 min at room temperature. Slides were washed
with PBS (5 min) and placed into a Shandon Sequenza as
described above. The tissue was blocked with 2.5% normal
horse serum (Vector Laboratories) for 20 min followed by a
second blocking with the Antibody Dilution Buffer contain-
ing 5% goat serum for 45 min. Both blocking steps were
performed at room temperature. Samples were stained with
a primary antibody against p63 (1:100, Biocare Medical,
Cat. # CM163B) or Ki67 (1:100, mouse monoclonal IgG1,
Dako, Cat#M7240, clone MIB-1) diluted in the Antibody
Dilution Buffer overnight at 4°C. After washing with PBS
(3 × 10 min), the tissue was incubated with a horseradish
peroxidase (HRP) coupled secondary antibody (Universal
Anti-Mouse/Rabbit IG, Vector Laboratories) for 30 min at
room temperature. Samples were again washed with PBS
(3 × 10 min). The positive antibody signal was developed
by applying a colorimetric peroxidase substrate (3-amino-
9-ethylcarbazole (AEC) with high sensitivity substrate
chromogen (Dako, Cat# K3461)). Tissue was incubated
for 9 min at room temperature. Slides were washed with
distilled water (5 min), counterstained with Hematoxylin
1 (diluted 1:3 in tap water) for 15 s (Thermo Scientific),
and rinsed under running tap water until water ran clear.
Slides were mounted with faramount Aqueous Mounting
Media (Dako, Cat# S3025) using 1.5 coverslips (0.16 to
0.19 mm thickness) (Fisher Scientific, Cat# 12-544B). Per-
cent Ki67 was quantified per patient manually by a certi-
fied pathologist based on positive immunohistochemical
staining in the nucleus above background.
Analysis of expression array datasets
Published gene expression dataset of normal breast tissue
and breast cancer tissue GSE3744 was downloaded from
GEO at NCBI. Data were analyzed using BioConductor
modules (http://www.bioconductor.org). Non-microdis-
sected tissues were used in this analysis. eBioConductor
affy module was used to perform background subtraction
and quantile normalization using the Robust MultiChip
Algorithm (RMA). Quality control analysis was done on
the chips that included correlation plots, density plots, box
plots, and RNA degradation analysis. ANOVA (Analysis of
Variance) was used to estimate differential gene expression
between samples and groups. This was done using the Bio-
Conductor limma module. Limma analysis provides an em-
pirical Bayesian method to improve variance estimation
and corrects for multiple hypothesis testing by the Benja-
mini Hochburg false discovery rate method. The log odds
that the gene is differentially expressed was provided by B-
statistics and greater than 3.0 was used as a cutoff for sig-
nificantly changing genes [17]. A heat map was generated
for cancer samples by comparing against averaged normal
samples for fold change differences. A color-coded heat
Figure 1 (See legend on next page.)
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Figure 1 Primary cilia expression lost early in breast cancer development. Serial sections of normal breast reduction mammoplasties (A)
and invasive breast cancer tissue (B). (A, B) Left: Tissue stained with hematoxylin and eosin (H&E). Inset shows a cross-section of a normal duct.
Middle: low magnification image showing nuclear staining (Hoechst). Dashed box indicates area of higher magnification represented in the adjacent
panel. Right: high magnification image showing tissue stained for cilia (acetylated tubulin, red) and centrosomes (γ-tubulin, green). Insets show a
magnified cilium (red) and its associated centrosome (green) in normal tissue (top panel) and the lack of a cilium in cancer (bottom panel). (C, D)
Boxplot represents percent ciliated cells in the following breast tissue types: basal epithelial cells of normal breast reduction mammoplasties (RM Basal,
n = 12), luminal epithelial cells of normal breast reduction mammoplasties (RM Luminal, n = 12), basal cells in histologically normal epithelium adjacent
to cancer (HNE Basal, n = 15), luminal cells in histologically normal epithelium adjacent to cancer (HNE Basal, n = 15), cancer cells in carcinoma
in situ lesions grades 1 and 2 combined (CIS 1&2, n = 23), cancer cells in carcinoma in situ grade 3 (CIS3, n = 16), cancer cells in invasive cancers
grades 1 and 2 combined (INV 1&2, n = 40), cancer cells in invasive cancer grade 3 (INV3, n = 25). The bar graph represents the percent of patients that
have an abnormally low percentage of ciliated cells (blue bars: quartile 1 (Q1), less than or equal to the 75th percentile for normal tissue) or
an abnormally high percentage of ciliated cells (orange bars: quartile 4 (Q4), greater than or equal to the 25th percentile for normal tissue).
(E) Percent of Ki67 positive invasive cancer cells per patient (y-axis) versus percent ciliated cancer cells for the same patient (x-axis). Statistical
significance (** = P <0.01, *** = P <0.001) was determined by performing logistic regression.
Menzl et al. Cilia Page 5 of 162014, 3:7
http://www.ciliajournal.com/content/3/1/7map was generated for visualization of increased or de-
creased expression of 69 cilia-associated genes.
To validate the changes in gene expression seen in the
Richardson dataset we performed a similar analysis of
the TCGA breast cancer dataset. We compared cilia-related
gene expression in normal breast tissue to invasive ductal
breast carcinoma using the Oncomine™ Platform (Life
Technologies, Ann Arbor, MI, USA). We analyzed gene
expression data from the TCGA dataset, obtained using
the same methodology. The gene expression data were
log transformed, median centered per array, and the
standard deviation was normalized to one per array [18].
A gene was considered as having decreased or increased
expression when its mean value in tumor samples was sig-
nificantly different to its mean value in the normal tissue
counterpart using a t-test (P ≤0.05).
Statistical analysis
Statistical significance of the relationship between per-
centage of ciliated cells and different tissue types (normal,
carcinoma in situ, and invasive cancer) were deter-
mined using logistic regression. The Hosmer-Lemeshow
goodness-of-fit test was used to confirm the overall fit of
the model. A P value of less than 5% was considered sig-
nificant. The correlation between percent cilia and Ki67
score of cancer was performed using a non-parametric
Spearman correlation. Differences in cilia length between
tissue types were tested using a linear mixed model with
Statistical Analysis System (SAS) Software. Statistical
significance of the relationship between cilia length and
different tissue types (normal, carcinoma in situ, and inva-
sive cancer) was determined using a linear mixed model
generated by the Statistical Analysis System (SAS) proced-
ure GLIMMIX. A P value, Bonferoni-adjusted for multiple
comparisons, of less than 5% was considered significant.
Boxplots were generated using the SigmaXL-Excel Add-in
(SigmaXL). Boxplots illustrate the data, where the 75th
and 25th percentiles are marked by the lower and upper
box limits, respectively. The black line within the boxdenotes the median. Outliers are defined as either <25th
percentile - 1.5× interquartile range, or >75th percentile +
1.5× interquartile range (open circles). Extreme outliers
were defined as either <25th percentile - 3× interquartile
range, or >75th percentile + 3× interquartile range (sold
circles).
Results
Cilia are absent on invasive breast cancer cells and their
pre-malignant lesions
We determined the primary cilia frequency in normal
human breast epithelium in vivo by immunofluorescent
staining of 12 specimens taken from normal breast reduc-
tion mammoplasties (RM) as well as 15 patients with his-
tologically normal epithelium adjacent to cancer (HNE).
We also examined the frequency of primary cilia on breast
cancer cells by staining tumor samples from 39 patients
with pre-malignant carcinoma in situ (CIS) and from 65
patients with invasive breast carcinoma (INV). The first
serial section was stained with H&E to identify areas of
normal, CIS, and INV. The H&E slide was used as a refer-
ence to find the tissue types of interest on the adjacent
serial section, which was stained with antibodies recogniz-
ing acetylated tubulin (Ac-Tub) to visualize primary cilia
and γ-tubulin (γ-Tub) to identify their associated cen-
trosomes (Figure 1A and 1B). Acetylated tubulin was
validated for use as a marker of primary cilia in these
tissue samples by co-staining with an antibody that
recognizes Arl13b, a well characterized marker of primary
cilia (Additional file 1: Figure S1). Ac-Tub and Arl13b
were observed to co-localize in cilia found on normal and
cancer tissues.
The normal mammary gland is composed of basal and
luminal epithelial cells that are separated from surround-
ing stromal cells by a basement membrane. Basal cells in
the mammary gland include both myoepithilial cells and
suprabasal cells [19]. We previously reported that basal
epithelial cells in the developing normal murine mammary
gland have a higher frequency of ciliated cells compared
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used basal position of epithelial cells as well as co-staining
with antibodies specific for basal cells including α-Smooth
Muscle Actin (α-SMA) and p63 to determine the frequency
of cilia on basal versus luminal epithelial cells in histologi-
cally normal human tissue (Additional file 1: Figure S2).
While primary cilia were expressed on both basal and
luminal epithelial cells, basal epithelial cells had a higher
cilia frequency (Basal: RM, median = 23.6%; HNE, me-
dian = 22.3%) than luminal epithelial cells (Luminal:
RM, median = 1.1%; HNE, median = 0.5%) (Figure 1A,
1C, and 1D). These results demonstrate that both basal
and luminal epithelial cells have cilia-positive cells and
that the frequency is higher for basal cells.
Invasive carcinoma (INV) of the breast is classified
into three grades (INV: I, 2, and 3) of increasing atypical
tissue and representing increased aggressive potential of
the tumor. INV-1 and INV-2 are often grouped together
as low-grade and INV-3 is considered high-grade. We
quantified cilia frequency on INV cancer cells and ob-
served a decrease in the percentage of ciliated cancer
cells in INV-1, INV-2, and INV-3 (Figure 1B, 1C, 1D).
The median percentage of ciliated cells in INV-1 and
INV-2 when combined (median = 0.2%; P <0.001) and
INV-3 (median = 0.2%; P <0.001) decreased significantly
compared to normal basal epithelial cells (Figure 1C, top
and Additional file 1: Table S1A). All (100%) of INV-1,
INV-2, and INV-3 patients had an abnormally low (falling
below the 75th percentile of normal, Q1) percentage of
ciliated epithelial cells compared to basal cells (Figure 1C,
bottom and Additional file 1: Table S1B). The median per-
centage of ciliated cells in INV-3 (median = 0.2%; P <0.01)
was also significantly decreased compared to normal lu-
minal epithelial cells (Figure 1D, top and Additional file 1:
Table S1A). While INV-1, INV-2 (median = 0.2%) did not
have a significant decrease in the percent ciliated cells
compared to normal luminal epithelial cells (Figure 1D,
top), we observed an increased number of INV-1, INV-2
(low grade), and INV-3 (high grade) patients (43% and
48%, respectively) with an abnormally low (below Q1) per-
centage of ciliated epithelial cells compared to luminal
cells (Figure 1D, bottom and Additional file 1: Table S1C).
To determine if loss of cilia occurs early in breast can-
cer development we quantified cilia in carcinoma in situ
(CIS) lesions, which represent a malignant, non-invasive
lesion that is thought to be a precursor to invasive cancer.
CIS is also classified into three grades (CIS: I, 2, and 3) of
increasing cellular atypia and decreased disease-free sur-
vival. CIS-1 and CIS-2 are grouped together as low-grade
and CIS-3 is considered high-grade. CIS cancer cells show
no evidence of invasion and are therefore contained
within a basement membrane border. We quantified cilia
frequency on all CIS cells within this basement membrane
and compared them to both normal basal and luminalepithelial cells. Loss of primary cilia was observed in CIS-1,
CIS-2, and CIS-3. The median percentage of ciliated cells
in CIS-1 and CIS-2 when combined (median = 0.8%;
P <0.001) and CIS-3 (median = 0.1%; P <0.001) decreased
significantly compared to normal basal epithelial cells
(Figure 1C, top and Additional file 1: Table S1A). All
(100%) of CIS-1, CIS-2, and CIS-3 patients had an abnor-
mally low (below Q1) percentage of ciliated epithelial cells
compared to basal cells (Figure 1C, bottom and Additional
file 1: Table S1B). While the median percentage of ciliated
cells in CIS-1, CIS-2 (median = 0.8%), and CIS-3 (median =
0.1%) was not significantly lower compared to normal
luminal epithelial cells (Figure 1D, top), an increased
number of CIS-3 patients (50%) had an abnormally low
(below Q1) percentage of ciliated epithelial cells compared
to luminal cells (Figure 1D, bottom and Additional file 1:
Table S1C). Loss of cilia observed on cells associated with
CIS lesions suggests that ciliary assembly defects occur
early in breast cancer development.
Loss of cilia during breast cancer development is not due
to increased proliferation or gross centrosomal defects
Ciliogenesis is a cell cycle regulated event. Primary cilia
are found on cells in G0 of the cell cycle. As cells re-
enter the cell cycle the cilium is resorbed into the cyto-
plasm [21]. Therefore, a possible cause of loss of cilia
on cancer cells could be decreased percentage of cells
in G0 phase of the cell cycle (increased proliferative
index). Ki67 is a protein expressed in all phases of the
cell cycle except G0 [22]. We therefore correlated per-
centage of ciliated cells to Ki67 positive cells in INV to
investigate if the loss of primary cilia in cancer cells is
due to a high proliferative index (Figure 1E). A statis-
tical correlation was not observed between low percent
cilia and high percent Ki67 in invasive breast cancer
samples (linear regression, R2 = 0.005). We found that
the majority of INV samples (84% of patients) had a
low proliferative index (<50% Ki67-positive cells). A
small fraction of INV samples (9% of patients) did indeed
have a high proliferative index (>80% Ki67-positive cells)
indicating that loss of cilia may be due to increased prolif-
eration in some patients. The percent Ki67-positive cells
therefore does not account for the low percentage of cilia
(median = 0.2%) observed in the majority of these breast
cancer patients.
Centrosome amplification has been observed in breast
cancer [23]. While we observed some breast cancer cells
with centrosome amplification, we also observed patient
samples with cancer cells with no evidence of centrosome
amplification. We next observed that cancer cells from pa-
tients with no evidence of centrosome amplification have
a significant decrease in the percentage of cilia compared
to normal cells (Figure 1B). These observations suggest
that, in some patients, loss of cilia is due to defects that
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amplification.
Cilia-positive cancer cells co-express cytokeratin 5
Cytokeratin 5 (CK5) is a marker of basal epithelial cells
and progenitor cells in the normal breast [24]. CK5 was
recently shown to also be a marker used in diagnosing
breast cancers in the basaloid group and is associated
with a poor prognosis [25]. To determine the frequency of
primary cilia on CK5-positive (CK5+) versus CK5-negative
(CK5-) cells in normal and cancer tissues we co-stained
the RM, HNE, and INV patient samples with markers
of cilia (acetylated tubulin and γ-tubulin) together with
an antibody that recognizes CK5. To verify that the
CK5 antibody used was specific, we compared it to an-
other commonly used CK5 monoclonal antibody (Leica
Micosystems, Inc.), and found the two CK5 antibodies
co-localized in our tissues (Additional file 1: Figure S2).
CK5+ cells were present in all normal breast epithelium
(Figure 2A). Primary cilia were found on both CK5- and
CK5+ normal epithelial cells. The median percentage of
ciliated CK5- basal epithelial cells in RM and HNE tissues
(median = 26.0% and 14.9%) was not significantly different
compared to CK5+ basal epithelial cells (median = 19.6%
and 23.5%) (Figure 2B and Additional file 1: Table S2A).
The overall median percentage of ciliated cells (CK5-
and CK5+ combined) in the four breast cancer subtypes
was not significantly different compared to one another
(median: luminal A = 0.2%, luminal B = 0.1%, Her2 = 0.5%,
and Triple Negative = 0.1%; Figure 2A, Additional file 1:
Table S2B). While the percentage of cancer cells with cilia
is low, we found that 29.1% of these rare ciliated cancer
cells were CK5+. We find CK5+ staining on these rare
cilia-positive cancer cells in all four breast cancer subtypes
including Luminal A, Luminal B, Her2, and Triple Nega-
tive (Figure 2B and Additional file 1: Table S2A). CK5+
staining separated out patients with a higher than the
median (above 0.5%) percentage of ciliated cancer cells
compared to the CK5- ciliated cancer group (Figure 2B).
Further investigation is needed to better understand the
significance of these rare ciliated, CK5+ cancer cells.
The frequency of ciliated stromal cells decreases as breast
cancer develops
The stromal environment that surrounds a cancer can
play a causal role in its development and metastasis [26].
Therefore, we investigated cilia changes on stromal cells.
Stromal cells were identified based on location and elon-
gated morphology (small round lymphocytes were excluded
from this analysis). Primary cilia frequency was calculated
on stromal cells surrounding normal breast (RM and HNE)
and breast cancers (CIS and INV) (Figure 3A).
The frequency of primary cilia on stromal cells associated
with CIS-1 and CIS-2 combined (median = 4.7%; P <0.001),CIS-3 (median = 1.3%; P <0.01), INV-1 and INV-2 com-
bined (median = 4.7%; P <0.001), INV-3 (median = 1.7%;
P <0.001), decreased compared to stromal cells associ-
ated with histologically normal RM (median = 18.4%)
(Figure 3B and Additional file 1: Table S3A). The types
of stromal cells (that is, fibroblasts, lymphocytes, and so
on) were not differentiated for this study. It is possible
that the decrease in the overall percent cilia observed in
the stroma is due to changes in the stromal cell type dis-
tribution during cancer development. These data also
raise the possibility that primary cilia are lost on stromal
cells associated with preinvasive and invasive breast
cancerous cells.
Cilia expressed on breast cancer and cancer-associated
stromal cells have abnormal lengths
To determine the potential functionality of cilia that are
present on breast cancer cells we measured their lengths.
Abnormally short and long cilia have been shown to cor-
relate with abnormal regulation of signal transduction
pathways such as Hedgehog signaling [1,27]. This suggests
that abnormal cilia length can be used as an indirect
measure of the functional state of cilia.
As cilia frequency was quantified we noted the presence
of rare, very long cilia expressed on breast cancer cells
(Figure 4A). The median cilia length was not significantly
different on cancer cells of CIS-1 & 2 (median = 0.79 μm),
CIS-3 (median = 1.27 μm), or INV-1 & 2 (median =
1.10 μm) compared to normal tissue. However, the me-
dian cilia length was significantly longer on cancer cells
of INV-3 (median = 1.20 μm; P <0.01) compared to cilia
length on cells associated with normal tissue (RM: me-
dian = 0.76 μm; HNE: median = 0.9 μm) (Figure 4B and
4C, top and Additional file 1: Table S4A). Nevertheless,
we did observe an increased number of CIS-1&2, CIS-3,
INV-1&2, and INV-3 patients (38%, 75%, 57%, and 77%
respectively) with cilia that were abnormally long (above
Q4) compared to normal RM and HNE (Figure 4B and
4C, bottom and Additional file 1: Table S4B).
No statistically significant difference was detected in
the median cilia length on stromal cells associated with
CIS-1 & 2 combined (median = 0.85 μm), CIS-3 (me-
dian = 0.78 μm; P = 0.15), INV-1 & 2 combined (me-
dian = 0.95 μm), or INV-3 (median = 0.93 μm) when we
compared cilia length on stromal cells associated with
normal tissue (RM: median = 1.00 μm; HNE: median =
0.68 μm) (Figure 4D, top and Additional file 1: Table
S4D). While median cilia lengths were not different,
we observed an increased number of HNE, CIS-1&2,
CIS-3, INV-1&2, and INV-3 patients (73%, 74%, 69%,
50%, and 46% respectively) that had cilia with abnor-
mally short (below Q1) cilia compared to normal RM
(Figure 4D, bottom and Additional file 1: Table S4E).
Taken together these findings may indicate that rare
Figure 2 Rare cilia-positive cancer cells are positive for Cytokeratin 5. (A) Images show nuclei (blue), cytokeratin 5 (white), cilia (red), and
centrosomes (green) in cells from the following tissue: reduction mammoplasties (RM) and histologically normal epithelium (HNE) adjacent to
cancer and invasive cancers of four different cancer subtypes: luminal A and luminal B, Her2-positive, and triple negative. Insets show a magnified
ciliated CK5-positive cell. (B) Boxplot represents median percent of cilia expressed on CK5-negative and CK5-positive cells in the following breast
tissue types: basal epithelial cells of normal breast reduction mammoplasties (RM Basal, n = 12), luminal epithelial cells of normal breast reduction
mammoplasties (RM Luminal, n = 12), basal cells in histologically normal epithelium adjacent to cancer (HNE Basal, n = 15), luminal cells in histologically
normal epithelium adjacent to cancer (HNE Basal, n = 15), cancer cells in invasive cancers of the four breast cancer subtypes (Luminal A (LUM A,
n = 37), Luminal B (LUM B, n = 10), Her2-positive (Her2+, n = 6), and Triple Negative (TN, n = 12)). Statistical significance (** = P <0.01, *** = P <0.001)
was determined by performing logistic regression compared to normal RM.
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cells have dysfunctional cilia.
Loss of primary cilia on breast cancers correlates with
decreased expression of genes required for ciliogenesis
To determine if alterations in the expression of ciliary-
associated genes plays a role in the loss of cilia we ex-
amined expression of genes required for ciliary assembly
(ciliogenesis) or ciliary function in human breast cancers.
We assembled a list of genes reported in the literature tobe associated with ciliogenesis and/or cilia-related genetic
disorders (ciliopathies) [2,28]. This list included 69 genes
from the following cilia-associated categories: Intrafla-
gellar Transport (IFT) complex A, IFT complex B, ciliary
motor subunits, BBSome complex proteins, and other
ciliopathy-associated genes. The human subject microarray
used for this analysis was carried out using a previously
published dataset [29]. We determined the average expres-
sion of each cilia-associated gene and performed ANOVA
(Analysis of Variance) between normal mammary tissue
Figure 3 Fraction of ciliated stromal cells decrease as breast cancer develops. (A) Image showing stromal cells (str) next to a normal duct
(left) or next to a cancer (ca) structure (right). Insets show cilia (acetylated tubulin, red) and their associated centrosomes ( -tubulin, green) on
stromal cells. (B) Boxplot represents percent of ciliated stromal cells in the following breast tissue types: normal breast reduction mammoplasties
(RM, n = 12), histologically normal epithelium adjacent to cancer (HNE, n = 15), carcinoma in situ lesions grades 1 and 2 combined (CIS 1&2,
n = 23), carcinoma in situ grade 3 (CIS3, n = 16), invasive cancers grades 1 and 2 combined (INV 1&2, n = 40), invasive cancer grade 3 (INV3, n = 25).
The bar graph represents the percent of patients that have an abnormally low percentage of ciliated stromal cells (blue bars: Quartile 1 (Q1), less than
or equal to the 75th percentile for normal tissue) or an abnormally high percentage of ciliated stromal cells (orange bars: quartile 4 (Q4), greater than
or equal to the 25th percentile for normal tissue). Statistical significance (** = P <0.01, *** = P <0.001) was determined by performing logistic regression
compared to normal RM.
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Gene expression was considered significantly different
between normal and cancer samples with adjusted P value
less than 0.05 and B value greater than 3.0. Among the 69
ciliary-associated genes analyzed, seven genes showed a
statistically significant decrease in expression in breast can-
cers (log fold change: DYNC2H1 = -0.66; IFT46 = -1.07;
PKD2 = -1.67; NPHP3 = -1.10; BBS2 = -1.51; BBS4 = -0.78;
TTC8 = -1.46) (Figure 5B and Additional file 1: Table S5).These data demonstrate that a subset of cilia-related genes
is commonly downregulated in breast cancers.
Next, we examined if this subset of cilia-related genes
is downregulated in a larger cohort of invasive ductal
breast carcinomas. We analyzed the full set of cilia-related
genes in the publically available TCGA breast cancer data-
set using Oncomine [18]. The gene expression data were
log transformed, median centered per array, and the
standard deviation was normalized to one per array for
Figure 4 (See legend on next page.)
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Figure 4 Cilia length abnormalities associated with breast cancer and their stromal cells. (A) Images of cilia representing typical lengths
on basal epithelial cell in normal breast reduction mammoplasties, on invasive cancer cells, on stromal cells associated with normal breast
reduction mammoplasties, and stromal cells associated with invasive cancers. (B, C) Boxplot represents median length of cilia expressed on cells
in the following breast tissue types: basal epithelial cells of normal breast reduction mammoplasties (RM Basal, n = 12), luminal epithelial cells of
normal breast reduction mammoplasties (RM Luminal, n = 12), basal cells in histologically normal epithelium adjacent to cancer (HNE Basal,
n = 15), luminal cells in histologically normal epithelium adjacent to cancer (HNE Basal, n = 15), cancer cells in carcinoma in situ lesions grades 1 and 2
combined (CIS 1&2, n = 23), cancer cells in carcinoma in situ grade 3 (CIS3, n = 16), cancer cells in invasive cancers grades 1 and 2 combined (INV 1&2,
n = 40), cancer cells in invasive cancer grade 3 (INV3, n = 25). (D) Boxplot represents the median length of cilia on stromal cells in the following breast
tissue types: normal breast reduction mammoplasties (RM, n = 12), histologically normal epithelium adjacent to cancer (HNE, n = 15), carcinoma in situ
lesions grades 1 and 2 combined (CIS 1&2, n = 23), carcinoma in situ grade 3 (CIS3, n = 16), invasive cancers grades 1 and 2 combined (INV 1&2,
n = 40), invasive cancer grade 3 (INV3, n = 25). (B-D) The bar graph represents the percent of patients that have an abnormally low percentage
of ciliated cells (blue bars: quartile 1 (Q1), less than or equal to the 75th percentile for normal tissue) or an abnormally high percentage of
ciliated cells (orange bars: quartile 4 (Q4), greater than or equal to the 25th percentile for normal tissue). (** = P <0.01) was determined by
performing logistic regression compared to normal RM.
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difference in gene expression between normal mammary
tissue (n = 61) and invasive ductal breast carcinoma
(n = 389). Of the seven identified in the Richardson data-
set above, six were also significantly downregulated in
the TCGA dataset (log fold change: DYNC2H1 = -2.35;
IFT46 = -1.17; PKD2 = -2.62; NPHP3 = -2.40; BBS2 = -1.91;
TTC8 = -1.31) (Additional file 1: Table S5). Gene expres-
sion was considered significantly different between normal
and cancer samples if the P value was less than 0.05. BBS4
was downregulated (log fold change -1.02) in the TCGA
dataset but this was not statistically significant (P = 0.28).
Nine additional cilia-related genes were significantly
downregulated when analyzed in the TCGA dataset;
however, these were not significantly downregulated in
the Richardson dataset (B value was less than 3). Also,
we did not identify genes in either dataset that showed a
statistically significant increase in expression in breast
cancers compared to normal tissues.
DYNC2H1 is a cytoplasmic dynein involved in intra-
flagellar transport in the cilium and therefore is required
for ciliogenesis. To determine if protein expression of
the cilia-related gene DYNC2H1 is decreased in breast
cancers we performed immunofluorescent staining of
three specimens taken from normal breast reduction
mammoplasties (RM) as well as five patients with invasive
breast carcinoma. Note that no other antibodies were
identified to the other six significantly downregulated cilia
genes that worked for staining of paraffin embedded tis-
sue. Staining of normal breast tissue demonstrated that
the basal and luminal cells both have highly positive stain-
ing for DYNC2H1 as compared to secondary only control.
Cancers cells have decreased positive signal in all five of
the breast cancers analyzed. All five of these breast can-
cers were also stained for primary cilia and showed very
low percentages of primary cilia. These data indicate that
DYNC2H1 protein expression is decreased in breast can-
cers. Loss of expression of DYNC2H1 has been shown to
have abnormal, shortened cilia due to the lack of transportof proteins from the tip of the cilium back to the cell
body (retrograde IFT) [30,31]. Decreased expression of
DYNC2H1 as well as the other ciliary-related genes may
turn off ciliogenesis and explain the loss of cilia seen in
breast cancers.
Discussion
We hypothesize that primary cilia loss is an early event
that promotes breast cancer development. We have
knocked out genes required for ciliogenesis (IFT88 and
Ki67) and found no evidence of tumor promotion in the
mammary glands of these mice [20]. Therefore, loss of
cilia does not appear to be sufficient to initiate tumori-
genesis in the mammary gland. We hypothesize the loss
of cilia cooperates/synergizes with other oncogenic events
to promote tumorigenesis. Indeed, loss of cilia has been
shown to cooperate with constitutive activation of the
Hh pathway (overexpression of constitutively active
Gli transcription factor) to promote tumorigenesis in
mouse models of basal cell carcinoma and medullo-
blastoma [5-7]. Overexpression of mutant forms of Gli
transcription factors has not been observed in breast
cancer patients. However, it is possible that loss of cilia
predisposes cancer cells to non-canonical activation of the
Hh pathway. Specifically, cilia are required for processing
of Gli3 into its repressor form. In normal cells, the Gli3-
repressor sits on Hh-target genes and blocks transcrip-
tional activation. Loss of cilia is therefore equivalent to
loss of the Gli3-repressor. We hypothesize that when cilia
are lost in cancer cells, the Hh-target genes are vulnerable
to activation by oncogenic transcription factors. Myc has
recently been shown to upregulate transcription of Hh-
target genes [32]. Our working model is that loss of cilia,
in the context of overexpression or increased activation of
oncogenic transcription factors such as Myc, will result in
increased Hh-target gene expression and thereby promote
tumorigenesis. Loss of cilia has also been reported to
abrogate other oncogenic signaling pathways including
increasing Wnt signaling [33,34]. Cross-reactivity with
Figure 5 Characterization of human breast cancer samples for expression of ciliogenesis genes. (A) Heat map displays the relative gene
expression change seen in basal-like cancer samples compared to normal breast tissue. Each column represents a breast cancer tissue sample
(sample name listed on top) and each row represents the relative expression results of a different ciliary gene (gene names are to the right).
Overexpression is depicted in red, and underexpression is depicted in green. (B) The boxplots represent distribution of expression values for individual
genes comparing breast cancer tissue samples to the normal tissues samples. The ciliary-associated genes shown in boxplots are those that were
found to be statistically significant by ANOVA (Analysis of Variance) between normal and basal-like cancer samples with adjusted *P value <0.05. The
log odds that the gene is differentially expressed are provided by B-statistics and B >3.0 was used as a cutoff for significantly changing genes. (C)
Images show staining of normal breast reduction mammoplaties or breast cancer tissue with secondary antibody alone or with an antibody recognizing
DYNC2H1 (red). Inset in normal breast tissue shows that tissue was also co-stained for antibodies to identify cilia (acetylated tubulin, green; -tubulin,
white) and analyzed for co-localization in the same cell. The arrow points to a cilium with a pool of DYNC2H1 at the base.
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cilia promote tumorigenesis.
A decrease in primary cilia expression was found in
pre-invasive breast carcinoma in situ (CIS). Not all pa-
tients with CIS will progress to invasive breast cancer.
However, there is molecular evidence that CIS is a precur-
sor to invasive disease and diagnosis with CIS represents
an increased risk of developing invasive breast cancer [35].
Understanding of the molecular mechanisms that underlie
these early stages of tumor development in breast cancer
is critical so that we can design targeted therapies for early
intervention. Identification of ciliary dysfunction in these
precursor lesions may indicate that cilia are involved in
early stages of breast cancer promotion and therefore pro-
vide a new target for therapy.
We also investigated the cause of loss of primary cilia
in breast cancers. We demonstrated that increased pro-
liferation and centrosome amplification did not account
for the loss of cilia seen in breast cancer. We also observe
that luminal epithelial cells have low expression of cilia
in normal breast tissue. If luminal cells are the tumor-
initiating cell for some cancer types, they may therefore
have this first ‘hit’ already in place, predisposing them to
oncogenic events that cooperate with absence of cilia.
We next examined expression of genes known to be in-
volved in the formation (ciliogenesis) and function of
the primary cilium. Ciliogenesis is a highly regulated
process [36]. Hundreds of proteins that localize to the
primary cilium have been identified by proteomic ana-
lysis [37-45]. Many of these proteins are involved in
ciliogenesis. Other proteins localized to the cilium are
involved in the sensory or signaling functions of the pri-
mary cilium. Transport machinery that is critical for
both ciliogenesis as well as ciliary sensory function is
mediated by a process known as intraflagellar transport
(IFT) [46,47]. The Kinesin-2 motor complex transports
the IFT complex as well as other protein ‘cargo’ for an-
terograde movement of proteins to the tip of the cilium
(plus end of microtubules). The cytoplasmic Dynein 2
motor complex transports the IFT complex plus ‘cargo’ for
retrograde movement from the tip of the cilium towards
the cell body (minus end of microtubules). The IFT com-
plex is made up of several proteins and mutations in IFT
genes cause loss of ciliary assembly and consequently re-
sult in loss of sensory functions [48]. Another complex of
proteins (BBSome complex) is also required for ciliogen-
esis and for targeted delivery of proteins into the cilium
[49]. Mutations in IFT, BBSome, and other ciliary genes
that are required for ciliogenesis and ciliary function are
now known to be causal for a large number of genetic
disorders classified as ciliopathies. Ciliopathies include
Joubert syndrome (JBTS), polycystic kidney disease (PKD),
Bardet-Biedl syndrome (BBS), and nephronophthisis (NPHP)
[50]. We assembled a list of 69 ciliary-associated genes fromthe following categories: Intraflagellar Transport (IFT)
complex A, IFT complex B, ciliary motor subunits, BBSome
complex proteins, and other ciliopathy-associated genes.
We observed decreased expression of genes from each
of these categories (downregulation of DYNC2H1, IFT46,
PKD2, NPHP3, BBS2, BBS4, and TTC8) in two separate
microarray datasets. We further validated downregulation
of DYNC2H1 protein expression in breast cancers. De-
creased expression of these cilia-related genes is known to
abrogate ciliogenesis and/or ciliary function and therefore
may explain the loss of cilia seen in breast cancers.
DYNC2H1 is a cytoplasmic dynein required for intraflagel-
lar transport. Indeed, loss of DYNC2H1 expression alone is
known to be sufficient to abrogate ciliogenesis [30,31].
Further work is needed to understand if the decreased ex-
pression of these cilia-related genes is due to an altered
transcriptional program or genomic instability.
While the majority of breast cancer cells were devoid
of primary cilia, we observed rare cilia-expressing cancer
cells. We measured the length of these ciliary axonemes
and found that many of the remaining ciliated cells had
ciliary axonemes that were abnormally long (longer than
ciliary axonemes found on normal epithelial cells). In-
creases in ciliary length are known to be triggered by
environmental or molecular/genetic events. For example,
cilia found on renal epithelial cells have increased length
in response to renal injury [51]. Also, changes in the actin
cytoskeleton result in increased ciliary length [52]. Finally,
mutations in MKS3 that are associated with the human
ciliopathy Meckel-Gruber syndrome have many of the
phenotypic hallmarks of ciliopathies (renal cysts, central
nervous system defects, and polydactyly) and the associ-
ated cilia are longer than normal [53]. This increased
ciliary length associated with a ciliopathy suggests that
increases in the length of the ciliary axoneme can abrogate
ciliary function.
The rare ciliated cancer cells found in invasive breast
cancer samples frequently co-expressed cytokeratin 5
(CK5). CK5 is expressed in progenitor cells that can give
rise to luminal and myoepithelial lineages [54]. In basal-like
breast tumors, CK5 is a marker of poor prognosis [55]. In
addition, CK5+ breast cancer cells have been shown to be
more resistant to chemotherapy than CK5- cancer cells
[24,56,57]. Detection of cilia on the CK5+ breast cancer
cells may provide a new molecular target for therapies to
eradicate these chemo-resistant cells in patients.
We observed a decrease in the fraction of ciliated stro-
mal cells associated with pre-invasive and invasive breast
cancer. The remaining cilia found on stromal cells were
shorter than cilia found on normal stromal cells. Absence
of an elongated ciliary axoneme has been associated with
ciliary dysfunction in a number of animal models and hu-
man diseases [2]. Together these finding suggest that there
is ciliary dysfunction on stromal cells during breast cancer
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environment surrounding cancer cells is an important
regulator of breast cancer development. Boyd et al. have
demonstrated that mammographically dense breasts have
an increased risk in developing breast cancer [58]. This
increased breast density is attributed to increased cellular
and extracellular matrix components in the stroma.
The cellular changes in cancer-associated stroma include
changes in the number and activation of carcinoma-
associated fibroblasts [59,60]. The activation of cancer-
associated fibroblasts is thought to alter the environment
by changing the composition of growth factors and ECM
proteins and thereby plays a role in breast cancer de-
velopment. Our observation of ciliary dysfunction in
breast cancer-associated stroma prompts the need for
future studies to examine the role of cilia on cancer-
associated fibroblasts to determine if loss of stromal
cilia contributes to breast cancer development.
Our findings have shown that breast cancer cells have
a very low frequency of primary cilia. An important
question for therapeutics is whether this loss of primary
cilia is a driver of breast cancer. Loss of cilia has been
associated with increased Hedgehog signaling in mouse
models of cancer [5,6]. Hedgehog-targeted drugs are be-
ing investigated both in clinical trials and in laboratories.
Most of these drugs inhibit Smoothened (Smo), a positive
regulator of the pathway that requires primary cilia to be
functional [3]. Since primary cilia are lost in breast tu-
mors, we hypothesize that breast cancer patients would
not be good candidates for Smo-inhibitor drugs. However,
treatment of patients with a cilia-independent Hedgehog
pathway inhibitor may be efficacious [3].
Conclusions
In the present study, we determined that ciliogenesis is
decreased in low- and high-grade invasive breast cancers.
Our studies also revealed for the first time that primary
cilia expression was lost on pre-invasive breast cancer
lesions demonstrating that this is an early event in can-
cer development. Furthermore, cilia expression and
function were decreased on cancer-associated stromal
cells. Finally, we correlated loss of cilia with downregu-
lation of genes required for ciliogenesis and/or ciliary
function in human breast cancers. Future studies are
needed to test this hypothesis and determine if ciliary dys-
function plays a causal role in breast cancer development.
Additional file
: Supplementary Figures and Tables.
Abbreviations
α-SMA: α-smooth muscle actin; γ-tub: γ-tubulin; Ac-Tub: Acetylated tubulin;
ANOVA: Analysis of variance; BBS: Bardet-Biedl syndrome; ca: Cancer;
Additional file 1CIS: Carcinoma in situ; CK5: Cytokeratin 5; H&E: Hematoxylin and Eosin;
HNE: Histologically normal epithelium adjacent to cancer; IFT: Intraflagellar
transport; INV: Invasive cancer; LUM A: Luminal A subtype; LUM B: Luminal B
subtype; Q1: Quartile 1; Q4: Quartile 4; RM: Reduction mammoplasties;
str: Stroma; TN: Triple negative subtype.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
IM and NBH carried out the staining and imaging of tissues, and drafted the
methods and figures. LL and RN analyzed all normal and cancer pathology.
RP and FWL analyzed microarray dataset and performed statistical analysis.
KW assembled the breast cancer cohort. KMM conceived and designed the
study and participated in writing of the manuscript. All authors read and
approved the final manuscript.
Acknowledgements
The authors would like to acknowledge Tom Bunch, and Martha Nunez for
feedback and scientific discussions. We would like to thank the TACMASS
members for tissue processing and H&E staining. We would also like to
thank Lynn Rychter and Robert Hers off in the Department of Pathology for
digitally scanning tissue slides. Finally, we would also like to acknowledge
Vern Harts, Denise Roe, and Kathy Lynn Abode for assistance with statistical
analysis. Funding was provided by the Cancer Center Support Grant, National
Cancer Institute, NIH, P30CA023074 (K. M. McDermott); Cancer Biology Training
Grant, National Cancer Institute, NIH, T32CA009213 (N. B. Mascoutah); R00,
National Institute of Child Health and Human Development, NIH, R00HD056965
(K. M. McDermott). Funding sources did not play a role in the design, in the
collection, analysis, interpretation of data, writing of the manuscript, or decision
to submit for publication.
Author details
1The University of Arizona Cancer Center, University of Arizona, Tucson, AZ,
USA. 2Department of Pathology, University of Arizona Medical Center,
Tucson, AZ, USA. 3Department of Cellular and Molecular Medicine, University
of Arizona, Tucson, AZ, USA. 4Department of Psychiatry, University of Arizona
Medical Center, Tucson, AZ, USA. 5Bio5 Institute, University of Arizona,
Tucson, AZ, USA.
Received: 14 February 2014 Accepted: 29 May 2014
Published:
References
1. Goetz SC, Anderson KV (2010) The primary cilium: a signalling centre during
vertebrate development. Nat Rev Genet 11:331–344
2. Hildebrandt F, Benzing T, Katsanis N (2011) Ciliopathies. N Engl J Med
364:1533–1543
3. Hassounah NB, Bunch TA, McDermott KM (2012) Molecular pathways: the
role of primary cilia in cancer progression and therapeutics with a focus on
Hedgehog signaling. Clin Cancer Res 18:2429–2435
4. Basten SG, Giles RH (2013) Functional aspects of primary cilia in signaling,
cell cycle and tumorigenesis. Cilia 2:6
5. Wong SY, Seol AD, So PL, Ermilov AN, Bichakjian CK, Epstein EH Jr, Dlugosz
AA, Reiter JF (2009) Primary cilia can both mediate and suppress Hedgehog
pathway-dependent tumorigenesis. Nat Med 15:1055–1061
6. Han YG, Kim HJ, Dlugosz AA, Ellison DW, Gilbertson RJ, Alvarez-Buylla A (2009)
Dual and opposing roles of primary cilia in medulloblastoma development.
Nat Med 15:1062–1065
7. Barakat MT, Humke EW, Scott MP (2013) Kif3a is necessary for initiation and
maintenance of medulloblastoma. Carcinogenesis 34:1382–1392
8. Schraml P, Frew IJ, Thoma CR, Boysen G, Struckmann K, Krek W, Moch H
(2009) Sporadic clear cell renal cell carcinoma but not the papillary type is
characterized by severely reduced frequency of primary cilia. Mod Pathol
22:31–36
9. Kim J, Dabiri S, Seeley ES (2011) Primary cilium depletion typifies cutaneous
melanoma in situ and malignant melanoma. PLoS ONE 6:e27410
10. Seeley ES, Carriere C, Goetze T, Longnecker DS, Korc M (2009) Pancreatic
cancer and precursor pancreatic intraepithelial neoplasia lesions are devoid
of primary cilia. Cancer Res 69:422–430
01 Jul 2014
Menzl et al. Cilia Page 15 of 162014, 3:7
http://www.ciliajournal.com/content/3/1/711. Gradilone SA, Radtke BN, Bogert PS, Huang BQ, Gajdos GB, LaRusso NF
(2013) HDAC6 inhibition restores ciliary expression and decreases tumor
growth. Cancer Res 73:2259–2270
12. Egeberg DL, Lethan M, Manguso R, Schneider L, Awan A, Jorgensen TS,
Byskov AG, Pedersen LB, Christensen ST (2013) Primary cilia and aberrant
cell signaling in epithelial ovarian cancer. Cilia 1:15
13. Hassounah NB, Nagle R, Saboda K, Roe DJ, Dalkin BL, McDermott KM (2013)
Primary cilia are lost in preinvasive and invasive prostate cancer. PLoS ONE
8:e68521
14. Basten SG, Willekers S, Vermaat JS, Slaats GG, Voest EE, van Diest PJ, Giles
RH (2013) Reduced cilia frequencies in human renal cell carcinomas versus
neighboring parenchymal tissue. Cilia 2:2
15. Yuan K, Frolova N, Xie Y, Wang D, Cook L, Kwon YJ, Steg AD, Serra R, Frost
AR (2010) Primary cilia are decreased in breast cancer: analysis of a
collection of human breast cancer cell lines and tissues. J Histochem
Cytochem 58:857–870
16. Nobutani K, Shimono Y, Yoshida M, Mizutani K, Minami A, Kono S,
Mukohara T, Yamasaki T, Itoh T, Takao S, Minami H, Azuma T, Takai Y (2014)
Absence of primary cilia in cell cycle-arrested human breast cancer cells.
Genes Cells 19:141–152
17. Wettenhall JM, Smyth GK (2004) LimmaGUI: a graphical user interface for
linear modeling of microarray data. Bioinformatics 20:3705–3706
18. Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D, Barrette
T, Pandey A, Chinnaiyan AM (2004) ONCOMINE: a cancer microarray
database and integrated data-mining platform. Neoplasia 6:1–6
19. Visvader JE (2009) Keeping abreast of the mammary epithelial hierarchy and
breast tumorigenesis. Genes Dev 23:2563–2577
20. McDermott KM, Liu BY, Tlsty TD, Pazour GJ (2010) Primary cilia regulate
branching morphogenesis during mammary gland development. Curr Biol
20:731–737
21. Pan J, Snell W (2007) The primary cilium: keeper of the key to cell division.
Cell 129:1255–1257
22. Scholzen T, Gerdes J (2000) The Ki-67 protein: from the known and the
unknown. J Cell Physiol 182:311–322
23. Lingle WL, Barrett SL, Negron VC, D’Assoro AB, Boeneman K, Liu W,
Whitehead CM, Reynolds C, Salisbury JL (2002) Centrosome amplification
drives chromosomal instability in breast tumor development. Proc Natl
Acad Sci U S A 99:1978–1983
24. Axlund SD, Yoo BH, Rosen RB, Schaack J, Kabos P, Labarbera DV, Sartorius
CA (2013) Progesterone-inducible cytokeratin 5-positive cells in luminal
breast cancer exhibit progenitor properties. Horm Cancer 4:36–49
25. Inanc M, Ozkan M, Karaca H, Berk V, Bozkurt O, Duran AO, Ozaslan E, Akgun
H, Tekelioglu F, Elmali F (2014) Cytokeratin 5/6, c-Met expressions, and PTEN
loss prognostic indicators in triple-negative breast cancer. Med Oncol
31:801
26. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation.
Cell 144:646–674
27. Broekhuis JR, Leong WY, Jansen G (2013) Regulation of cilium length and
intraflagellar transport. Int Rev Cell Mol Biol 303:101–138
28. Bhogaraju S, Engel BD, Lorentzen E (2013) Intraflagellar transport complex
structure and cargo interactions. Cilia 2:10
29. Richardson AL, Wang ZC, De Nicolo A, Lu X, Brown M, Miron A, Liao X,
Iglehart JD, Livingston DM, Ganesan S (2006) X chromosomal abnormalities
in basal-like human breast cancer. Cancer Cell 9:121–132
30. Schmidts M, Arts HH, Bongers EM, Yap Z, Oud MM, Antony D, Duijkers L,
Emes RD, Stalker J, Yntema JB, Plagnol V, Hoischen A, Gilissen C, Forsythe E,
Lausch E, Veltman JA, Roeleveld N, Superti-Furga A, Kutkowska-Kazmierczak
A, Kamsteeg EJ, Elcioglu N, van Maarle MC, Graul-Neumann LM, Devriendt K,
Smithson SF, Wellesley D, Verbeek NE, Hennekam RC, Kayserili H, Scambler PJ
et al (2013) Exome sequencing identifies DYNC2H1 mutations as a common
cause of asphyxiating thoracic dystrophy (Jeune syndrome) without major
polydactyly, renal or retinal involvement. J Med Genet 50:309–323
31. Dagoneau N, Goulet M, Genevieve D, Sznajer Y, Martinovic J, Smithson S,
Huber C, Baujat G, Flori E, Tecco L, Cavalcanti D, Delezoide AL, Serre V, Le
Merrer M, Munnich A, Cormier-Daire V (2009) DYNC2H1 mutations cause
asphyxiating thoracic dystrophy and short rib-polydactyly syndrome, type III.
Am J Hum Genet 84:706–711
32. Yoon JW, Gallant M, Lamm ML, Iannaccone S, Vieux KF, Proytcheva M, Hyjek
E, Iannaccone P, Walterhouse D (2013) Noncanonical regulation of the
Hedgehog mediator GLI1 by c-MYC in Burkitt lymphoma. Mol Cancer Res
11:604–61533. Corbit KC, Shyer AE, Dowdle WE, Gaulden J, Singla V, Chen MH, Chuang PT,
Reiter JF (2008) Kif3a constrains beta-catenin-dependent Wnt signalling
through dual ciliary and non-ciliary mechanisms. Nat Cell Biol 10:70–76
34. Lancaster MA, Schroth J, Gleeson JG (2011) Subcellular spatial regulation of
canonical Wnt signalling at the primary cilium. Nat Cell Biol 13:700–707
35. Benson JR, Wishart GC (2013) Predictors of recurrence for ductal carcinoma
in situ after breast-conserving surgery. Lancet Oncol 14:e348–e357
36. Pazour GJ, Rosenbaum JL (2002) Intraflagellar transport and cilia-dependent
diseases. Trends Cell Biol 12:551–555
37. Ostrowski LE, Blackburn K, Radde KM, Moyer MB, Schlatzer DM, Moseley A,
Boucher RC (2002) A proteomic analysis of human cilia: identification of
novel components. Mol Cell Proteomics 1:451–465
38. Li JB, Gerdes JM, Haycraft CJ, Fan Y, Teslovich TM, May-Simera H, Li H, Blacque
OE, Li L, Leitch CC, Lewis RA, Green JS, Parfrey PS, Leroux MR, Davidson WS,
Beales PL, Guay-Woodford LM, Yoder BK, Stormo GD, Katsanis N, Dutcher SK
(2004) Comparative genomics identifies a flagellar and basal body proteome
that includes the BBS5 human disease gene. Cell 117:541–552
39. Smith JC, Northey JG, Garg J, Pearlman RE, Siu KW (2005) Robust method
for proteome analysis by MS/MS using an entire translated genome:
demonstration on the ciliome of Tetrahymena thermophila. J Proteome Res
4:909–919
40. Pazour GJ, Agrin N, Leszyk J, Witman GB (2005) Proteomic analysis of a
eukaryotic cilium. J Cell Biol 170:103–113
41. Gherman A, Davis EE, Katsanis N (2006) The ciliary proteome database: an
integrated community resource for the genetic and functional dissection of
cilia. Nat Genet 38:961–962
42. Inglis PN, Boroevich KA, Leroux MR (2006) Piecing together a ciliome.
Trends Genet 22:491–500
43. Wagner V, Gessner G, Heiland I, Kaminski M, Hawat S, Scheffler K, Mittag M
(2006) Analysis of the phosphoproteome of Chlamydomonas reinhardtii
provides new insights into various cellular pathways. Eukaryot Cell
5:457–468
44. Liu Q, Tan G, Levenkova N, Li T, Pugh EN Jr, Rux JJ, Speicher DW, Pierce EA
(2007) The proteome of the mouse photoreceptor sensory cilium complex.
Mol Cell Proteomics 6:1299–1317
45. Mayer U, Kuller A, Daiber PC, Neudorf I, Warnken U, Schnolzer M, Frings S,
Mohrlen F (2009) The proteome of rat olfactory sensory cilia. Proteomics
9:322–334
46. Rosenbaum JL, Witman GB (2002) Intraflagellar transport. Nat Rev Mol Cell
Biol 3:813–825
47. Scholey JM (2003) Intraflagellar transport. Annu Rev Cell Dev Biol
19:423–443
48. Pazour GJ (2004) Intraflagellar transport and cilia-dependent renal disease:
the ciliary hypothesis of polycystic kidney disease. J Am Soc Nephrol
15:2528–2536
49. Nachury MV, Seeley ES, Jin H (2010) Trafficking to the ciliary membrane:
how to get across the periciliary diffusion barrier? Annu Rev Cell Dev Biol
26:59–87
50. Ware SM, Aygun MG, Hildebrandt F (2011) Spectrum of clinical diseases
caused by disorders of primary cilia. Proc Am Thorac Soc 8:444–450
51. Verghese E, Weidenfeld R, Bertram JF, Ricardo SD, Deane JA (2008) Renal
cilia display length alterations following tubular injury and are present early
in epithelial repair. Nephrol Dial Transplant 23:834–841
52. Kim J, Lee JE, Heynen-Genel S, Suyama E, Ono K, Lee K, Ideker T, Aza-Blanc P,
Gleeson JG (2010) Functional genomic screen for modulators of ciliogenesis
and cilium length. Nature 464:1048–1051
53. Tammachote R, Hommerding CJ, Sinders RM, Miller CA, Czarnecki PG,
Leightner AC, Salisbury JL, Ward CJ, Torres VE, Gattone VH 2nd, Harris PC
(2009) Ciliary and centrosomal defects associated with mutation and
depletion of the Meckel syndrome genes MKS1 and MKS3. Hum Mol Genet
18:3311–3323
54. Rios AC, Fu NY, Lindeman GJ, Visvader JE (2014) In situ identification of
bipotent stem cells in the mammary gland. Nature 506:322–327
55. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR,
Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu
SX, Lonning PE, Borresen-Dale AL, Brown PO, Botstein D (2000) Molecular
portraits of human breast tumours. Nature 406:747–752
56. Kabos P, Haughian JM, Wang X, Dye WW, Finlayson C, Elias A, Horwitz KB,
Sartorius CA (2011) Cytokeratin 5 positive cells represent a steroid receptor
negative and therapy resistant subpopulation in luminal breast cancers.
Breast Cancer Res Treat 128:45–55
Menzl et al. Cilia Page 16 of 162014, 3:7
http://www.ciliajournal.com/content/3/1/757. Lim E, Vaillant F, Wu D, Forrest NC, Pal B, Hart AH, Asselin-Labat ML, Gyorki
DE, Ward T, Partanen A, Feleppa F, Huschtscha LI, Thorne HK, kConFab, Fox
SB, Yan M, French JD, Brown MA, Smyth GK, Visvader JE, Lindeman GJ
(2009) Aberrant luminal progenitors as the candidate target population for
basal tumor development in BRCA1 mutation carriers. Nat Med 15:907–913
58. Boyd NF, Dite GS, Stone J, Gunasekara A, English DR, McCredie MR, Giles
GG, Tritchler D, Chiarelli A, Yaffe MJ, Hopper JL (2002) Heritability of
mammographic density, a risk factor for breast cancer. N Engl J Med
347:886–894
59. Pavelka N, Rancati G, Li R (2011) Dr Jekyll and Mr Hyde: role of aneuploidy
in cellular adaptation and cancer. Curr Opin Cell Biol 22:809–815
60. Dumont N, Liu B, Defilippis RA, Chang H, Rabban JT, Karnezis AN, Tjoe JA,
Marx J, Parvin B, Tlsty TD (2013) Breast fibroblasts modulate early
dissemination, tumorigenesis, and metastasis through alteration of
extracellular matrix characteristics. Neoplasia 15:249–262
Cite this article as: Menzl et al.: Loss of primary cilia occurs early in
breast cancer development. Cilia
10.1186/2046-2530-3-7
2014, 3:7Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
